ExoLytics, Inc.

ROCKVILLE, MD · Founded 2020 · Biotech · Private

Engineered endolysins and phage-derived lysins for treating antibiotic-resistant bacterial infections

Claim this profile

Follows are private to you and power your alerts

Updated · exolytics.com

Sector
Biotech
Headquarters
ROCKVILLE, MD
Founded
2020
Latest Form D
$10K, Sep 2020
Total capital
$10K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$10K
1 Form D · last Sep 2020
73 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

2020FEDERAL ↑EQUITY ↓Cumulative $10K1st Form D$10K
2020FEDERAL ↑EQUITY ↓Cumulative $10K1st Form D$10K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$10K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Daniel C NelsonExecutive Officer, DirectorNamed in SEC Form D filings
  • Khola C AslamDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • HepGene, Inc.Similar federal contract value in Biotech · null in contracts
  • Compvide Inc.Similar federal contract value in Biotech · null in contracts
  • Magellan Bioscience Group IncSimilar federal contract value in Biotech · null in contracts
  • Ntxbio, LLCSimilar federal contract value in Biotech · null in contracts
  • BIOADAPTIVES, INC.Similar federal contract value in Biotech · null in contracts
  • NABLA BIO, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .